ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025
Association of MC1R variants with melanoma risk and interaction with sun exposure: An M-SKIP project.
Abstract readLetter
In one paragraph
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Germline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.Pigment cell & melanoma research · 2025Article
- Screening and novel diagnostic technologies for melanoma: an update.Melanoma management · 2025Review
- Germline Non-CDKN2A Variants in Melanoma and Associated Hereditary Cancer Syndromes.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Irene Stefanaki1st Clinic of Dermatological and Venereal Diseases, Medical School National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athina, Greece.ORCID https://orcid.org/0000-0002-2964-370X
Oriana D'EcclesiisDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Silvano VignatiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Aurora GaetaDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Katerina Kypreou1st Clinic of Dermatological and Venereal Diseases, Medical School National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athina, Greece.
Saverio CainiCancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research Prevention and Clinical Network (ISPRO), Florence, Italy.
Sara GandiniDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
Francesco SeraDepartment of Statistics, Computer Science and Applications G. Parenti, University of Florence, Florence, Italy.
Francesca BottaDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Julia Newton-BishopInstitute of Medical Research at St James's, University of Leeds, Leeds, UK.
David PolskyNew York University School of Medicine, NYU Langone Medical Center, New York, New York, USA.
DeAnn LazovichDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.
Peter A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Susana PuigMelanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.ORCID https://orcid.org/0000-0003-1337-9745
Nelleke A GruisDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Maria Concetta FargnoliDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-7249-2556
Alexander Stratigos1st Clinic of Dermatological and Venereal Diseases, Medical School National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athina, Greece.
Gabriella GuidaDepartment of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "A. Moro", Bari, Italy.
Paola GhiorzoDepartment of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
Chiara MeninDiagnostic Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
José C García-BorrónDepartment of Biochemistry, Molecular Biology and Immunology, University of Murcia and IMIB-Arrixaca, Murcia, Spain.
Julian LittleSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Hongmei NanDepartment of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin & Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, USA.
Sara RaimondiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
M‐SKIP study group
Funding
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0MMolecular Epidemiology of MelanomaR01CA092428 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2002 to 2006
$2.3MRETINOID IN CHEMOPREVENTION OF PRIMARY MELANOMAP01CA075434 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GUERRY, DUPONT · 1997 to 2000
$935kMELANOMA AND ALLELIC VARIATION IN THE MCIR GENEK07CA080700 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2000 to 2005
$634kAGAUR 2017_SGR_1134 of the Catalan Government, SpainCIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund "A way to achieve Europe" ERDFCR UK C588/A19167, C8216/A6129 and C588/A10721 and NIH CA83115Division of Cancer Prevention, National Cancer Institute CA092428Division of Cancer Prevention, National Cancer Institute CA75434Division of Cancer Prevention, National Cancer Institute CA80700European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, DiagnopticsFundació La Marató de TV3" 201331-30, Catalonia, Spain"Fundación Científica de la Asociación Española Contra el Cáncer" GCB15152978SOEN, Spain, and CERCA Programme / Generalitat de CatalunyaIRCCS Ospedale Policlinico San MartinoNCI NIH HHS K07 CA080700NCI NIH HHS R01 CA083115NCI NIH HHS R01 CA092428Spanish Fondo de Investigaciones Sanitarias PI15/00716Spanish Fondo de Investigaciones Sanitarias PI15/00956Spanish Fondo de Investigaciones Sanitarias PI18/00419Spanish Fondo de Investigaciones Sanitarias PI18/01077The Italian Association for Cancer Research MFAG 11831The National Cancer Institute CA83115
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.